NPCE – neuropace, inc. (US:NASDAQ)
Stock Stats
News
NeuroPace (NASDAQ:NPCE) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
NeuroPace (NASDAQ:NPCE) had its price target raised by analysts at JPMorgan Chase & Co. from $18.00 to $20.00. They now have an "overweight" rating on the stock.
NeuroPace (NASDAQ:NPCE) had its "buy" rating reaffirmed by analysts at UBS Group AG.
NeuroPace Announces Positive 18-Month NAUTILUS Trial Results in Idiopathic Generalized Epilepsy
NeuroPace to Highlight Life-Changing Outcomes and AI-Powered Confident Care at the 2025 American Epilepsy Society (AES) Annual Meeting [Yahoo! Finance]
Form 4 NeuroPace Inc For: Dec 03 Filed by: Morrell Martha
Form 4 NeuroPace Inc For: Nov 27 Filed by: Becker Joel
Form 4 NeuroPace Inc For: Nov 27 Filed by: Morrell Martha
Form 4 NeuroPace Inc For: Nov 20 Filed by: Morrell Martha
Form SCHEDULE 13G/A NeuroPace Inc Filed by: Soleus Private Equity Fund I, L.P.
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.